|
|
||||||||
Department of Medicine, Division of Endocrinology and Metabolism and Departments of Nuclear Medicine ami Pathology, Faculté de Médecine,Université de Sherbrooke, Québec, Canada
Correspondence: For correspondence or reprints contact: Pierre Maheux, MD, Division of Endocrinology and Metabolism, Centre Universitaire de Santé de I'Estrie (Fleurimont), 3001, 12ème Avenue Nord, Sherbrooke, Québec, J1H 5N4, Canada.
ABSTRACT
The aim of this study was to assess the relationship between parathyroid oxyphil cell content and early or late phases of uptake of 99mTc-MIBI, a radioisotope preferentially retained in mitochondria-rich cells. Methods: This study is a retrospective, single-blind analysis of all double-phase 99mTc-MIBI parathyroid scintigraphy studies performed before surgery in our institution between 1990 and 1995. A total of 18 parathyroid lesions in 14 patients were reviewed. This sample included 11 cases of primary hyperparathyroidism (8 adenomas, 1 adenocarcinoma and 2 hyperplasias) and 3 cases of tertiary hyperparathyroidism secondary to chronic renal failure. Results: Uptake of 99mTc-MIBI in the early phase of scintigraphy was associated with larger parathyroid lesions (1.61 ± 1.61 ml versus 0.33 ± 0.27 ml;p < 0.02) and higher serum calcium levels (3.00 ± 0.41 mM versus 2.67 ± 0.14 m/W;p < 0.02). More importantly, we found that a parathyroid oxyphil cell content greater than 25% was more often associated with a positive uptake of 99mTc-MIBI in the late phase of the test (positive late uptake in 78% of lesions with a high oxyphil cell content versus 33% in lesions with an oxyphil cell content between 1%and 25% and 0% in lesions with no oxyphil cells; p < 0.04). Conclusion: These findings suggest that the late retention of 99mTc-MIBI in double-phase scintigraphy is related to parathyroid oxyphil cell content.
Key Words: hyperparathyroidism technetium-99m-MIBI oxyphil cells parathyroid adenoma
This article has been cited by other articles:
![]() |
A. E. Stephen, S. I. Roth, D. W. Fardo, D. M. Finkelstein, G. W. Randolph, R. D. Gaz, and R. A. Hodin Predictors of an Accurate Preoperative Sestamibi Scan for Single-Gland Parathyroid Adenomas Arch Surg, April 1, 2007; 142(4): 381 - 386. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Bleier, V. A. LiVolsi, A. A. Chalian, P. A. Gimotty, J. D. Botbyl, and R. S. Weber Technetium tc 99m sestamibi sensitivity in oxyphil cell-dominant parathyroid adenomas. Arch Otolaryngol Head Neck Surg, July 1, 2006; 132(7): 779 - 782. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Y. Mehta, J. M. Ruda, S. Kapadia, P. J. Boyer, C. S. Hollenbeak, and B. C. Stack Jr Relationship of Technetium Tc 99m Sestamibi Scans to Histopathological Features of Hyperfunctioning Parathyroid Tissue Arch Otolaryngol Head Neck Surg, June 1, 2005; 131(6): 493 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Mariani, S. A. Gulec, D. Rubello, G. Boni, M. Puccini, M. R. Pelizzo, G. Manca, D. Casara, G. Sotti, P. Erba, et al. Preoperative Localization and Radioguided Parathyroid Surgery J. Nucl. Med., September 1, 2003; 44(9): 1443 - 1458. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |